Pramipexole in restless legs syndrome
✍ Scribed by Mauro Manconi; Ilaria Casetta; Vittorio Govoni; Edward Cesnik; Luigi Ferini-Strambi; Enrico Granieri
- Publisher
- Springer
- Year
- 2003
- Tongue
- English
- Weight
- 141 KB
- Volume
- 250
- Category
- Article
- ISSN
- 0340-5354
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract We evaluated the efficacy of pramipexole versus placebo in restless legs syndrome (RLS) for 6 weeks. Overall, 345 patients were randomly assigned in a 1:2 ratio to receive either placebo (n = 115) or pramipexole (n = 230) with a starting dose of 0.125 mg/day. The dose was individually o
## Abstract **Background**: Pramipexole and ropinirole have become the first‐line treatment for restless legs syndrome. The aim of this study was to perform the first direct comparison between these two molecules in restless legs syndrome. **Methods**: A double‐blind, placebo‐controlled, double‐nig
## Abstract Although dopamine agonists are becoming first‐line therapy for restless legs syndrome (RLS), few reports describe treatment periods exceeding 12 weeks. Here, 150 RLS patients who had responded to pramipexole during a 6‐month run‐in period (mean dose, 0.50 mg) were randomly assigned to r
## Abstract Restless legs syndrome (RLS) and Tourette's syndrome (TS) share some common features, including the phenomenology of sensations relieved by movements, but few studies have examined the links between RLS and TS. We examined RLS and other TS comorbidities in 144 probands with TS or chroni